# Primer Capital

> Primer Capital is a VC fund in Moscow backing Health Care and Medical. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Moscow, Russian Federation
- Total investments: 7
- Last investment: Oct 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/primer-capital/
- Website: http://primer-capital.com/en/
- Facebook: https://www.facebook.com/vcprimercapital

PRIMER CAPITAL is a venture capital fund focusing on investments in companies engaged in development of promising biotech and medical products for various pharmaceutical sectors.Our qualified managing Team is interested in a high-quality selection of projects that form our portfolio. Our team of qualified consultants and Scientific AdvisoryBoard consisting of top experts in various medical, biopharmaceutical, and business fields contribute considerably to successful project selection.We cooperate with venture capital funds, business angels, government agencies interested in the development of biopharmaceutical industry, medical institutions and laboratories. Our many years’ experience and in-depth knowledge of the industry ecosystem provides portfolio companies with all opportunities for a quick start and establishment of effective relationships with their key partners throughout the whole period of its growth. Primer Capital co-invests in projects with leading venture capital funds and assists portfolio companies in fundraising.

## Contacts

5 contacts available for Primer Capital. Shizune tracks 2 team members at Primer Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/primer-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 57% |
| Medical | 3 | 43% |
| Biotechnology | 3 | 43% |
| Pharmaceutical | 2 | 29% |
| FinTech | 1 | 14% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Convertible Note | 2 | 29% |
| Seed | 1 | 14% |
| Series B | 1 | 14% |
| Funding Round | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 43% |
| Israel | 1 | 14% |
| Mexico | 1 | 14% |
| Russian Federation | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Elizaveta Rozhdestvenskaya | COO | 0 | — |
| Maria Belousova | CEO | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nelo | Nelo develops a mobile application for financial transactions. It began operation on April 8, 2019, with its headquarters in Mexico City. | $20M | Series A | Oct 12, 2021 |  |
| MatriSys Bioscience | MatriSys sees commercialization paths for its intellectual property in topical dermatology therapeutics, cosmetics, and skin care. The company’s lead live biologic therapeutic is currently in Phase I/II clinical trials targeting atopic dermatitis (commonly referred to as AD or eczema) patients. | $3M |  | Mar 11, 2021 |  |
| MatriSys Bioscience | MatriSys sees commercialization paths for its intellectual property in topical dermatology therapeutics, cosmetics, and skin care. The company’s lead live biologic therapeutic is currently in Phase I/II clinical trials targeting atopic dermatitis (commonly referred to as AD or eczema) patients. | $3M | Convertible Note | Mar 11, 2021 |  |
| Botkin.AI | Botkin.AI is a software-based platform for medical image processing and analysis based on artificial intelligence. The Company provides AI for analyzing radiograms and diagnosing the risk of tumors. The solution is based on deep machine learning. Botkin.AI significantly expands the radiologists’ ability to diagnose tumors and speeds up theprocessing of an increased flow of the patient’s clinical data without losing the quality of medical conclusions.It was founded in 2015 and is based in Moscow, Russian. | $1.7M | Series B | Dec 23, 2020 |  |
| Athira Pharma | Athira Pharma is a clinical-stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders.Athira is derived from the word Athir, the energy that reaches everyone. It captures its mission to develop therapies that can reachand positively impact everyone. |  | Convertible Note | Sep 04, 2020 |  |
| Bendit | Bendit is a medical company that develops and manufactures innovative catheters based on a unique bending technology, enabling extensive steering abilities in micro diameter and conventional catheter wires and tubes. The company is a joint venture between three experienced groups from production, quality & regulation, and development in themedical field. | $3.6M | Series A | Sep 03, 2017 |  |
| MiNDERA Corporation | MiNDERA Dx conducts research and development on non-invasive molecular testing for skin cancer and other skin diseases. The company is currently focused on a technology solution to extract skin biomarkers in a non-invasive manner. It was founded in 2013 and is based in San Francisco, United States. |  | Seed | Dec 01, 2016 |  |

7 of 7 investments shown.

## Co-investors
- [TCA Venture Group](https://shizune.co/investors/profile/tech-coast-angels) — VC Fund, 2 deals together
- [Trajectory Ventures](https://shizune.co/investors/profile/trajectory-ventures) — VC Fund, 2 deals together
- [Crossbeam Venture Partners](https://shizune.co/investors/profile/crossbeam-venture-partners) — VC Fund, 1 deal together
- [Orbita Capital Partners](https://shizune.co/investors/profile/digital-evolution-ventures) — VC Fund, 1 deal together
- [ExpoCapital](https://shizune.co/investors/profile/expocapital) — VC Fund, 1 deal together
- [Gaingels](https://shizune.co/investors/profile/gaing) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Primer Capital invest in?

Primer Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Convertible Note stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Primer Capital?

Public channels for Primer Capital include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Primer Capital?

The team at Primer Capital includes Elizaveta Rozhdestvenskaya (COO) and Maria Belousova (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co